• Par Pharmaceutical recalls drug lot because of silicone particles

    Par Pharmaceutical, an Endo International company, recalled one lot of treprostinil injection solutions because of the potential presence of silicone particles, the FDA said March 12. 
  • Transform Your Hospital Operations: A Virtual Summit

    Sponsored
    Nearly 190 health systems are reimagining hospital operations with AI. Learn how, here.
  • Eli Lilly, Amazon partner on weight loss drug delivery

    Eli Lilly has tapped Amazon Pharmacy as a partner to deliver select medications including weight loss drugs directly to consumers' homes.
  • In a 1st, Seattle Children's to test CAR T-cell drug among children with lupus

    Seattle Children's is the first FDA-authorized site to deliver an experimental CAR T-cell therapy to children with lupus, the system said March 11. 
  • 340B sees growth, remains small share of drug companies' revenue: Report

    A new report from Healthsperien, prepared for the American Hospital Association, found that while the 340B program is still a minor portion of the drug industry revenue, its growth has provided significant benefits to a large number of underserved U.S. patients and communities.
  • ASHP seeks executive director for End Drug Shortages Alliance

    The American Society of Health-System Pharmacists is leading a national search for an executive director to helm the End Drug Shortages Alliance. 
  • After study failure, Amylyx might pull ALS drug from market

    A phase 3 study of Amylyx Pharmaceuticals' approved therapy for amyotrophic lateral sclerosis, Relyvrio, failed to find significant efficacy results. By mid-June, the drugmaker might withdraw the drug. 
  • Syphilis drug shortage persists, expected to end in Q4

    Pfizer's shortage of penicillin G benzathine injection, an antibiotic for syphilis and other bacterial infections, is now predicted to last until the end of 2024. 
  • Diabetes drug costs grew 129% in 5 years: GoodRx

    Compared to 2018, the average diabetes patient now spends 129% more for their medications — largely affecting patients taking GLP-1s like Ozempic and Mounjaro, according to GoodRx. 
  • The case for DPYD testing in cancer patients, per ASHP

    National clinical guidelines don't mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of Health-System Pharmacists reported March 6. 
  • Wegovy approved for cardiovascular indications

    Wegovy, Novo Nordisk's weight loss therapy part of a popular drug class, is now approved for reducing the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease and are either obese or overweight, the FDA said March 8. 
  • Pharmacist group addresses second victim syndrome

    It's past time to support pharmacists during times of crisis and patient care failures, which can cause second victim syndrome, according to American Pharmacists Association CEO Michael Hogue, PharmD. 
  • FDA delays decision on Eli Lilly Alzheimer's drug

    The FDA has informed Eli Lilly that it plans to convene a panel of independent experts to learn more about the safety and efficacy of donanemab, the company's proposed Alzheimer's drug. The move delays an FDA decision on the drug until at least later this year.
  • Mark Cuban's drug startup: 2 years later

    Two years after launching a company with a few dozen discounted generics, Mark Cuban's Cost Plus Drugs now offers more than 2,000 medications, partners with hundreds of independent and grocery chain pharmacies, and manufactures its own drugs. 
  • CDC shares 1st real-world data on RSV drug

    Nirsevimab, a new monoclonal antibody treatment for respiratory syncytial virus, was 90% effective at preventing hospitalizations among infants this virus season, according to a March 7 CDC report.
  • Drugmaker to cap inhaler costs

    Boehringer Ingelheim will cap out-of-pocket costs for its inhaler products at $35 per month starting in June. 
  • After 20 years of failure, HIV vaccine research takes a turn

    Trials for experimental HIV vaccines have been fruitless for the last two decades, but recent scientific advances are spurring optimism among researchers, NBC News reported March 6. 
  • Mark Cuban's drug company partners with 1st health system

    On March 7, Franklin, Tenn.-based Community Health Systems became the first hospital system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co.
  • FDA panel backs simplified flu shot for next season

    An FDA advisory panel has unanimously recommended the agency approve a trivalent, rather than quadrivalent, flu vaccine for use next season.
  • 10 drugs poised to be best-sellers in 2024

    Merck's cancer drug Keytruda is expected to be the top-selling drug globally in 2024, according to data published by Statista.
  • FDA clears 1st OTC glucose monitor

    The FDA on March 5 cleared the Dexcom Stelo Glucose Biosensor System for use, making it the first continuous glucose monitoring device to be available over the counter.

Featured Whitepapers

Featured Webinars